Cefixime3日間連続投与後の前立腺組織内濃度について

Abstract

TURを受けた前立腺肥大症54症例を対象として, 経尿道的前立腺切除術にて切除した前立腺組織と同時に採取した血液にて組織内濃度を測定した.これら54例の年齢は56歳～86歳(平均69.5歳)であった.200 mg最終投与後約17時間のPのみが, 16症例中12症例で検出限界以下であったが, 検出された4症例では0.38～1.38 μg/g(平均0.83±0.49 μg/g)で, Sは0.24～2.58 μg/ml(平均0.84±0.63 μg/ml)であった.また検出された4症例について計算したP/Sは0.32～0.64(平均0.47±0.14)であった.午後に手術を施行した38症例では, 200 mg最終投与後5.5時間でのPは0.33～2.69 μg/g(平均1.08±0.47 μg/g)で, Sは1.24～6.89 μg/ml(平均3.18±1.28 μg/ml)であった.またP/Sは0.16～0.56(平均0.35±0.10)であった

The penetration of Cefixime (CFIX) into the prostatic tissue and the serum was examined in 54 patients with benign prostatic hypertrophy treated with transurethral resection of the prostate. CFIX was administered orally in a dose of 200 mg 2 times daily for 3 days preoperatively. The blood samples were taken at the time of the tissue sampling. The patients were divided into 2 groups. In group 1 (16 patients), the tissue sampling was done about 17 hours after the final drug administration. The mean concentration of CFIX was 0.83 +/- 0.49 micrograms/g in the prostatic tissue and 0.84 +/- 0.63 micrograms/ml in the serum. In the prostatic tissue, CFIX was detected in only 4 patients, in the other 12 patients, CFIX was not detected. In group 2 (38 patients), tissue sampling was done 5.5 hours after the final drug administration. The mean concentration of CFIX was 1.08 +/- 0.47 micrograms/g in the prostatic tissue and 3.18 +/- 1.28 micrograms/ml in the serum.